We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Impel

News List

Impel NeuroPharma Announces NDA Acceptance of INP104 for Acute Migraine americanpharmaceuticalreview
January 25, 2021
Impel NeuroPharma announced the U.S. Food and Drug Administration (FDA) has accepted for review the company's 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults.
Impel NeuroPharma Announces Last Patient Enrolled in INP104 Trial for Migraine americanpharmaceuticalreview
September 05, 2019
Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use...
Impel raises $67.5M as it eyes filing for nasal migraine drug fiercebiotech
December 29, 2018
Impel NeuroPharma’s championing of the nasal delivery route for drugs has been rewarded with a fourth-round financing that will help it advance three projects through the clinic.....
Impel NeuroPharma Closes $67.5 Million Series D Financing firstwordpharma
December 06, 2018
Impel NeuroPharma ("Impel" or the "Company"), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has complet